Literature DB >> 8227796

Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy.

R S Beanlands1, D S Bach, R Raylman, W F Armstrong, V Wilson, M Montieth, C K Moore, E Bates, M Schwaiger.   

Abstract

OBJECTIVES: The aim of this study was to use positron emission tomography (PET)-derived carbon (C)-11 acetate kinetics to determine the effects of dobutamine on oxidative metabolism and its effects on myocardial efficiency in a group of patients with dilated cardiomyopathy.
BACKGROUND: Dobutamine is known to improve myocardial function but may do so at the expense of myocardial oxygen consumption, which could be a potential deleterious effect. Carbon-11 acetate kinetics correlate with myocardial oxygen consumption as shown in animal models. Combining these scintigraphic measurements of oxygen consumption with estimates of cardiac work results in a work-metabolic index, which reflects cardiac efficiency.
METHODS: Eight patients with nonischemic dilated cardiomyopathy underwent dynamic PET imaging, echocardiography and hemodynamic measurements. Seven of these patients were also studied while receiving dobutamine. Direct measurements of myocardial oxygen consumption using coronary sinus catheterization were obtained with eight of the PET studies to validate C-11 acetate in patients with cardiomyopathy.
RESULTS: The mean (+/- SD) C-11 clearance rate significantly increased with dobutamine from 0.105 +/- 0.027 to 0.155 +/- 0.023 min-1 (p = 0.001). Directly measured myocardial oxygen consumption had a linear relation to the mean C-11 clearance rate (r = 0.8, p = 0.018). Dobutamine was noted to significantly reduce systemic vascular resistance as well as the severity of mitral regurgitation. The work-metabolic index determined using hemodynamic variables and PET data increased from 2 +/- 0.7 x 10(4) to 2.6 +/- 0.6 x 10(4) (p = 0.04). Efficiency, estimated by employing the oxygen consumption to k2 relation, also increased from 13 +/- 4.5% to 16.9 +/- 6.4% (p = 0.04).
CONCLUSIONS: Despite an increase in myocardial oxygen consumption, dobutamine led to an increase in work-metabolic index in patients with dilated nonischemic cardiomyopathy. Dobutamine reduced systemic vascular resistance and mitral regurgitation, suggesting that in this group of patients, it had important vasodilatory action in addition to its inotropic effects. The use of the C-11 acetate PET for determining myocardial oxygen consumption and estimating efficiency could potentially complement existing clinical measures of ventricular performance and may allow improved and objective evaluation of therapy in patients with heart failure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8227796     DOI: 10.1016/0735-1097(93)90548-f

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  25 in total

1.  BMIPP compared with PET metabolism.

Authors:  E Tadamura; N Tamaki; T Kudoh; N Hattori; J Konishi
Journal:  Int J Card Imaging       Date:  1999-02

2.  Myocardial Energetics in Heart Failure With Preserved Ejection Fraction.

Authors:  Omar F AbouEzzeddine; Bradley J Kemp; Barry A Borlaug; Brian P Mullan; Atta Behfar; Sorin V Pislaru; Marat Fudim; Margaret M Redfield; Panithaya Chareonthaitawee
Journal:  Circ Heart Fail       Date:  2019-10-15       Impact factor: 8.790

3.  Creation of clinically relevant model of chronic heart failure: Application of multi-modality imaging to define physiology.

Authors:  Stephanie Thorn; Albert J Sinusas
Journal:  J Nucl Cardiol       Date:  2015-02-20       Impact factor: 5.952

4.  PET-based myocardial efficiency: Powerful yet under-utilized-now simpler than ever.

Authors:  Frank M Bengel
Journal:  J Nucl Cardiol       Date:  2018-08-10       Impact factor: 5.952

5.  Myocardial oxidative metabolic supply-demand relationships in patients with nonischemic dilated cardiomyopathy.

Authors:  Marvin W Kronenberg; Gerald I Cohen; Marlo F Leonen; Thomas A Mladsi; Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2006-07       Impact factor: 5.952

6.  Myocardial oxidative metabolism, blood flow and efficiency in rapid pacing induced heart failure in dogs.

Authors:  Michel De Pauw; Jacques Melin; Marc De Buyzere; Guy R Heyndrickx
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2014-12-15

7.  Impairment of subendocardial perfusion reserve and oxidative metabolism in nonischemic dilated cardiomyopathy.

Authors:  Susan P Bell; Douglas W Adkisson; Henry Ooi; Douglas B Sawyer; Mark A Lawson; Marvin W Kronenberg
Journal:  J Card Fail       Date:  2013-10-29       Impact factor: 5.712

8.  Anaesthetic induction in a child with end-stage cardiomyopathy.

Authors:  W S Schechter; C Kim; M Martinez; B F Gleason; D P Lund; F A Burrows
Journal:  Can J Anaesth       Date:  1995-05       Impact factor: 5.063

9.  Acute improvement of cardiac efficiency measured by 11C-acetate PET after cardiac resynchronization therapy and clinical outcome.

Authors:  Kenji Kitaizumi; Kazushi Yukiiri; Hisashi Masugata; Hiroyuki Takinami; Yasuyoshi Iwado; Takahisa Noma; Naohisa Hosomi; Koji Ohmori; Shoichi Senda; Masakazu Kohno
Journal:  Int J Cardiovasc Imaging       Date:  2009-12-04       Impact factor: 2.357

Review 10.  Metabolic imaging using PET.

Authors:  Takashi Kudo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-05       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.